Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $85.97 USD
Change Today +0.73 / 0.86%
Volume 81.4K
NVS On Other Exchanges
SIX Swiss Ex
As of 9:33 AM 12/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056


Phone: 41 61 324 11 11


tion, USP; AirFluSal Forspiro; Kerydin (tavaborole) topical solution, 5%; Vitaros (alprostadil); Dexmethylphenidate ER (Focalin XR); Tobramycin inhalation solution, USP (TOBI); Calcipotriene and betamethasone dipropionate ointment, (Taclonex, Leo Pharma); Adapalene gel (Differin, Galderma Laboratories); Lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP (PREVPAC, Takeda Pharmaceuticals); Decitabine (Dacogen, Eisai); Escitalopram (Cipralex, Lundbeck); and Mometasone (Nasonex, Merck Sharp & Dohme). Sales and Marketing: Sandoz division sells a portfolio of generic pharmaceutical products to wholesalers, pharmacies, hospitals and other healthcare outlets. Significant Events The company discontinued the following businesses: Vaccines: Preventive human vaccines and the blood transfusion diagnostics unit, which was divested on January 9, 2014; and Consumer Health: OTC (OTC medicines) (following the January 1, 2015 completion of the divestment of Animal Health Division to Lilly, the Consumer Health segment consists only of the OTC Division). In March 2015, Novartis announced that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD. In July 2015, Aequus Pharmaceuticals Updates on Definitive Agreement to acquire TeOra Health LENGTH:Â 948 words Aequus Pharmaceuticals reported that it has entered into a definitive agreement to acquire TeOra Health as part of its growth strategy to build a commercial arm in Canada. In August 2015, Amgen announced neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. In October 2015, Sandoz, the generics division of Novartis, has stated its support for approval of the Trans-Pacific Partnership (TPP) trade agreement by Mexico. In November 2015, Thermo Fisher Scientific entered an agreement with Novartis and Pfizer to develop a next-generation sequencing-based (NGS) companion diagnostic (CDx) test. In November 2015, Thermo Fisher Scientific entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal sequencing (NGS) oncology test that will serve as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) across multiple drug development programs. History Novartis AG was founded in 1895.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $85.97 USD +0.73

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $314.11 USD +0.22
Gilead Sciences Inc $106.12 USD +0.16
Johnson & Johnson $101.34 USD +0.0999
Nestle SA SFr.76.10 CHF -0.25
Pfizer Inc $32.85 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 25.0x
Price/Sales 4.1x
Price/Book 2.7x
Price/Cash Flow 11.2x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVARTIS AG-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at